

## **Lion Biotechnologies Announces Clinical Data Update at American Society of Hematology Annual Meeting**

November 21, 2014 12:35 PM ET

### **NCI's Dr. Steven Rosenberg to Present New TIL Trial Data in Scientific Symposium**

LOS ANGELES, Nov. 21, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs) under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), today announced that Steven A. Rosenberg, M.D. Ph.D., chief of surgery at the NCI and principal investigator of the CRADA, will provide an update on a Phase 2 clinical trial in patients with metastatic melanoma at the American Society of Hematology (ASH) annual meeting in San Francisco. The data will be presented in a special scientific symposium on adoptive T-cell therapy (ACT) to treat cancers on December 7<sup>th</sup> from 9:30 to 11:00 a.m. PST.

The symposium, which will feature presentations by Drs. Rosenberg and Carl H. June, from the University of Pennsylvania's Perelman School of Medicine, will focus on the development of ACT, including TIL and chimeric antigen receptor T-cell therapy, which have demonstrated potentially curative efficacy in treating solid tumors and hematological malignancies. Dr. Rosenberg's presentation will cover solid tumor applications, including an update on the Phase 2 study of TIL therapy in metastatic melanoma that NCI is conducting under its CRADA with Lion.

A renowned surgeon and researcher and early pioneer of ACT, Dr. Rosenberg developed the technology on which Lion's TIL therapy is based. In clinical trials, TIL therapy has demonstrated robust efficacy in the treatment of metastatic melanoma, with objective response rates of about 50%.

For more information on the ASH symposium, click [here](#).

### **About Lion Biotechnologies**

Lion Biotechnologies, Inc. is engaged in the development of T cells and engineered T cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanoma and is based on a clinical CRADA with the NCI along with physician-sponsored investigational therapy at the MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute. For more information, please visit <http://www.lionbio.com>.

CONTACT: Investor Relations  
The Trout Group  
Gitanjali Jain Ogawa  
646-378-2949  
[gogawa@troutgroup.com](mailto:gogawa@troutgroup.com)

Source: Lion Biotechnologies, Inc.

Released November 21, 2014